Moreover, subsets of AML patients display varying degrees of network plasticity defining in vivo susceptibility to PI3K-AKT-mTOR inhibition, which has been shown to be most effective in patients with low levels of constitutive signaling (Nepstad et al., 2018). Here, MTOR is linked to acute myeloid leukemia.